Andicon Bio Announces Over RMB 200 Million Series A Financing to Advance Innovative Therapeutics in Respiratory Infections and Pain

Recently,Andikang (Wuxi) Biotechnology Co., Ltd.(hereinafter referred to as “Andikang Biotech”) officially announced the completion of its Series A financing round, exceeding RMB 200 million, led bySimcere (02096.HK), Huajin Investment, and Huajin AvenueCo-led by existing shareholdersCO-WIN Capital, Jiaxing Xinchuang Venture CapitalContinued Investment,Jiaxing Jiarui Future Star Equity Investment Partnership Enterprise (Limited Partnership), Jinsha River United Runpu Medical Fund, Wenzhou Capital, Songze Capital, and Shunjie HealthCo-investment. The funds raised will be used for the preclinical and clinical development of Andikang Biotechnology's core product pipeline, particularly to accelerate the pediatric clinical trials and commercialization of its independently developed Class 1 new anti-influenza drug, madonosavir (code name: ADC189), in tablet and granule formulations.

Andikang Biotechnology’s core pipeline candidate, the “one-dose cure” novel influenza drug madonosavir, has achieved significant clinical progress. Specifically, the multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical study evaluating the safety and efficacy of madonosavir tablets in adolescents and adults with uncomplicated acute influenza has met its primary endpoint. The median time to alleviation of all influenza symptoms was improved by 26.543% compared with the placebo group, a difference that was highly statistically significant (P<0.0001).The therapeutic efficacy for influenza B is superior to that of baloxavir marboxil (Xofluza).Demonstrates Excellent Safety and Efficacy. Furthermore, a Phase III multicenter, randomized, double-blind, double-dummy, active-controlled clinical study to evaluate the safety, pharmacokinetics, and efficacy of maridoxavir granules in pediatric influenza patients aged 2 to 11 years has been fully launched. Professor Ni Xin, Director of Beijing Children’s Hospital affiliated with Capital Medical University, and Professor Zhao Chengsong, Deputy Director of the hospital, jointly serve as the leading principal investigators (Leading PI) for this project,This studyCompletedIn35 Clinical Trial Centers NationwideConduct。

Andikang Biotechnology is an innovative pharmaceutical company dedicated to the development of novel therapeutics in the fields of respiratory infections and pain. Led by several academicians, its scientific innovation team comprises a group of highly qualified professionals who are both academically distinguished and pragmatically efficient. The company has established significant technical barriers across various stages of new drug creation, including innovative drug design and synthesis, DMPK technology research and application, and the research and development of advanced formulations tailored for special populations.Established an Innovative R&D System for Novel Small-Molecule Therapeutics Based on Metabolic DifferentiationIn addition to the pipeline for maridoxavir, a novel anti-influenza drug, the company’s product portfolio includes several innovative agents targeting respiratory pathogens, such as ADC789 suspension, a new drug against respiratory syncytial virus (RSV), and ADC101 suspension, a next-generation super-antibiotic against Mycoplasma. It also features ADC308 tablets, an innovative therapy for endometriosis and uterine fibroids that has the potential to fill a domestic treatment gap.

For this round of financing,Jiang Weiping, Chairman of Andikang Biotechnologystated, “We extend our sincere gratitude to both new and existing shareholders for their strong recognition of the Andikang team and its core technologies, as well as for their steadfast support. This round of financing will enable Andikang Biotechnology to secure regulatory approval and achieve commercial launch of all formulations of madonosavir, a novel influenza drug designed for ‘single-dose cure,’ while also providing robust support for the clinical development of our subsequent pipeline. Guided by clinical value, Andikang Biotechnology is accelerating the R&D of innovative drugs to bring new treatment options to patients at the earliest possible time, contributing Chinese wisdom and solutions that make curability and accessibility a reality for China’s public health security.”

SimcereChief Investment Officer Zhou Gaobo“We are delighted to partner with Andikang to bring a domestically developed innovative drug to the vast population of influenza patients each year. Marboxil is another anti-infective product from Simcere with differentiated advantages, following Xianuoxin. The alternating prevalence of influenza and COVID-19 may have a long-term impact on global public health, presenting a challenge that our pharmaceutical industry must confront. We look forward to working closely with the Andikang team to deliver more effective innovative therapies against influenza and contribute innovative strength to the cause of public health.”

Deng Huajin, Chairman of Huajin Avenue Investment Co., Ltd.stated, “It is a great honor for us to participate in this round of financing for Andikang Biotechnology. In the post-pandemic era, the public’s respiratory immune capacity has been compromised, leading to a significant increase in the pathogenicity and epidemic scale of influenza viruses, which continue to pose a threat to national health. As a new-generation specific anti-influenza drug, marudoxavir can achieve ‘single-dose cure and one-day viral clearance,’ demonstrating significant superiority over oseltamivir. It will build a new line of defense for the health of the Chinese population in the near future and contribute Chinese strength to the nation’s public health endeavors.”

CO-WINFoundingPartner Huang LiStatement: Over the past 24 years, CO-WIN has invested heavily in numerous healthcare projects. We place particular emphasis on technologies and products that address unmet clinical needs, prioritizing superior therapeutic efficacy and broader patient accessibility. In developing innovative drugs, it is essential not only to save lives but also to consider market scale; clinical market value serves as the core criterion for assessing the worth of new drugs. With a high incidence of influenza in China, the company’s independently developed next-generation anti-influenza drug offers broad population coverage and a high safety profile, enabling a “one-pill cure.” This provides a more convenient treatment option, especially for special populations such as children and adolescents. Meanwhile, we also look forward to progress in the company’s specialized pipeline areas, including anti-infectives and endometriosis. Andikang remains committed to independent innovation, and we are highly confident in growing alongside the enterprise.

Relevant Person in Charge at Huajin InvestmentStatement: There is a unique market demand for anti-influenza drugs in China. Anti-influenza drugs targeting the PA endonuclease have reached a new height as "influenza terminators," offering both therapeutic and prophylactic benefits with a single dose. This has been a target of our high attention and long-term tracking. Andikang has further enhanced its performance to match imported drugs through ingenious design, and it holds a leading domestic position in pediatric indications, a key market for influenza. We are delighted to participate in this project and work with all parties to advance the upgrade of influenza prevention and treatment in China.

Relevant Person in Charge of Jiaxing Xinchuang Venture CapitalStatement: We are delighted to participate in this round of financing for Andikang Biotechnology, marking our second investment in the company following its Pre-A round. The Andikang team is pragmatic and efficient, employing a unique approach to small-molecule innovative drug development based on metabolic differentiation. This strategy has accelerated the commercialization of Madoxovir, moving it rapidly from clinical trials to market availability, thereby strengthening domestic capabilities in public health security in the post-pandemic era. We will continue to monitor and support the company’s growth, looking forward to Andikang delivering more new products that are both curative and accessible to patients in China.

Person in Charge of Jiaxing Jiarui Future StarStatement: Influenza viruses exhibit significant epidemic potential and periodicity, indicating substantial market opportunities. Andikang Biotechnology has completed the Phase III clinical trials of madonosavir, a novel influenza drug designed for "single-dose cure." The results demonstrated favorable safety and efficacy profiles. Jiaxing Jiarui Future Star looks forward to the successful commercialization of madonosavir, the first fully self-developed Class 1 innovative drug in Jiaxing City. Like an aircraft carrier safeguarding public health, this venture sets sail from the birthplace of the Red Boat toward a bright future, benefiting patients in China and countries along the Belt and Road Initiative.

Jinsha River United Runpu Medical FundManagementPartner, Dr. Wang XiaoyanStatement: We are delighted to participate in this round of financing for Andikang Biotechnology. The company’s precise selection of indications, innovative drug design, composed problem-solving, and accurate grasp of key milestones demonstrate the team’s exceptional project initiation capabilities, efficient execution, and pragmatic, enterprising spirit. We look forward to working closely with the company to accelerate the market launch of the anti-influenza drug madunoxavir, and we are also highly optimistic about the future clinical success of its pipeline candidates.

Wang Liu, Partner at Wenzhou CapitalStatement: It is a great honor to participate in this round of financing for Andikang Biotechnology, working together to accelerate the market launch of madonosavir, a novel-mechanism anti-influenza drug, in China, thereby serving the vast population of influenza patients. The Andikang team possesses extensive experience in drug R&D, featuring a small-molecule research and development system with differentiated metabolic profiles, focusing on areas such as respiratory anti-infectives, and demonstrating high execution efficiency. Madonosavir tablets have met their primary endpoints in Phase II/III clinical trials, while the pediatric granule formulation has fully initiated Phase III clinical trials. Furthermore, the company maintains a robust pipeline of products targeting various respiratory pathogens, including viruses and Mycoplasma. We look forward to joint efforts from all parties to enable the company to provide patients with more innovative products that are both curative and accessible.

Yin Guilin, Partner at Songze CapitalStatement: It is a great honor to participate in Andikang’s current round of financing. Led by an academician, the company’s core R&D team boasts over 30 years of experience in the industrialization of new drugs. Since commencing formal operations in 2019, Andikang has advanced multiple product pipelines into clinical trials within just over four years. Notably, madonosavir, a Class 1 novel anti-influenza drug, has completed Phase III clinical trials and is expected to launch early next year. Requiring only a single dose for the entire course of treatment, it demonstrates superior disease control capabilities and offers a cost-effective domestic alternative, thereby providing an ideal therapeutic experience for patients in China. The company’s innovative drugs under development for endometriosis and respiratory syncytial virus (RSV) also hold significant clinical value. We look forward to Andikang becoming a great local healthcare enterprise.

Deng Zhihong, Chairman of Shunjie HealthStatement: It is a great honor to participate in this round of financing for Andikang Biotechnology. Compared with Xofluza, marboxil demonstrates superior clinical advantages, including greater efficacy in treating influenza B and oral administration that is not affected by food intake, highlighting its significant differentiated benefits. The scientific team at Andikang possesses a unique perspective in project initiation and accurately addresses unmet clinical needs. We firmly believe that, leveraging their outstanding team, advanced technology, and keen insight into market demands, Andikang will achieve greater breakthroughs and leaps in the future, deliver more innovative outcomes, and bring significant benefits to patients worldwide.

Simcere (02096.HK) is an innovation- and R&D-driven pharmaceutical company, home to the National Key Laboratory for Neurological and Oncological Drug Development. Simcere focuses primarily on oncology, neuroscience, autoimmune diseases, and anti-infectives, while proactively positioning itself in therapeutic areas with significant unmet clinical needs, committed to ensuring patients gain earlier access to more effective medicines. Driven by a dual-engine strategy of independent R&D and collaborative innovation, Simcere has established strategic partnerships with numerous innovative enterprises and academic research institutions.

Huajin Investment is an investment platform under Huafa Group, a state-owned enterprise in Zhuhai and one of China’s Top 500 Enterprises. With total assets exceeding RMB 700 billion, Huafa Group is the largest comprehensive corporate group in Zhuhai, ranking 169th on the “China Top 500 Enterprises” list. In the field of industrial investment, Huafa Group focuses on core sectors such as new energy, semiconductors, and healthcare. Its investment entities include multiple platforms such as Huajin Capital, Infinity Equity, and Zhuhai Science and Technology Innovation Investment. Among them, Huajin Capital has been repeatedly listed among Zero2IPO’s “Top 50 Private Equity Firms in China.” To date, Huafa Group has invested in nearly 400 industry-leading and high-growth innovative companies. Portfolio companies include Gokin Solar, Aiko Solar, Qinghai Lihao, CosMX Battery, Sunwoda, Naruida Radar, Chipone, and MGI Tech.

Huajin Avenue Investment Co., Ltd. is a wholly-owned subsidiary of Huajin Securities, with its headquarters located in Shanghai. As a core member of the financial industry cluster under Zhuhai Huafa Group, Huajin Securities is a fully licensed securities company. Leveraging the strategic location of Hengqin, Zhuhai, it has established a development positioning characterized by “regional focus, industrial focus, distinct features, and high-quality assets.” In recent years, Huajin Securities has received numerous industry accolades, being named “Most Growth-Oriented Securities Company of the Year” and “Outstanding Brokerage Firm of the Year,” among others, steadily enhancing its market position. The company currently operates nearly 20 branch offices and more than 30 brokerage business outlets across China. Huajin Securities provides high-quality, comprehensive services to support national strategic priorities and actively contributes to the development of the real economy.

CO-WIN Venture Capital is one of the first professional private equity investment firms in China, with 24Over [X] years of investment management experience, with assets under management exceeding350 billion yuan, cumulative invested enterprises700-plus, successfully boosting12Over 10 companies went public; investment in medical projectsSuper130 IPO-listed companiesSuper20 companies. The company has always taken industrial chain investment as its entry point, focusing on emerging industries and specializing in sub-sectors such as advanced technology, healthcare, and the digital economy. It has accumulated extensive experience in investing in hard-core technologies and frontier innovations. By adopting a prudent investment strategy, it deeply uncovers hidden champions, supports innovation and entrepreneurship, and is fully committed to serving the real economy.

Jiaxing Xinchuang Venture Capital is a state-owned fund manager under the Jiaxing Science and Technology City (Nanhu High-Tech Zone), formerly known as the Nanhu District Entrepreneurship Guidance Fund. With industrial guidance funds as its core, the company focuses primarily on three key sectors: microelectronics, intelligent equipment, and biopharmaceuticals, while also expanding into areas such as AI computing power and dual-carbon energy efficiency. It is a diversified state-owned venture capital institution covering multiple stages, including seed, angel, venture, equity, and mergers and acquisitions. Currently, Jiaxing Xinchuang Venture Capital’s invested projects in the pharmaceutical and healthcare sector include Zhengya Dental, Andikang Biotechnology, Edici, MicroPort UroTech, Heji Pharmaceutical, and Yashu Pharmaceutical.

Jiaxing Jiarui Future Star is a market-oriented sci-tech innovation fund jointly established by Jiaxing State-owned Investment and Huarui Investment. It aims to invest in early- to mid-stage sci-tech innovation enterprises that possess significant technological innovations, broad market prospects, and the potential to become future industry leaders. Since its establishment and operation, Jiaxing State-owned Investment has focused on equity investment as its core responsibility and main business, initiating and establishing multiple market-oriented funds. Seizing the opportunity to vigorously develop the “135N” advanced manufacturing cluster, it has made strategic investment layouts in emerging strategic industries such as intelligent manufacturing, new energy, new materials, and next-generation information technology. To date, the scale of fund investments has exceeded RMB 5 billion, leveraging over RMB 10 billion in total fund investments. By developing across multiple areas including capital operations, fund investment, and strengthening and supplementing industrial chains, it has fully promoted a new layout for state-owned capital investment and operation.

The Jinsha River United Runpu Medical Fund is the first medical fund focused on the healthcare sector, launched by Jinsha River United Capital in 2021. With over a decade of investment experience, the team has previously led investments in nearly 50 healthcare projects and possesses extensive industry resources. The fund primarily focuses on pharmaceuticals, in vitro diagnostics (IVD), and biotechnology, while also targeting high-quality early-stage and growth-stage companies. To date, the Runpu Medical Fund has invested in outstanding enterprises including Bowang Pharmaceuticals, Ruijian Medicine, Nurendjie Biotech, Joinn Laboratories, and Changyu Pharma.

Shanghai Wenzhou Capital Co., Ltd is a mixed-ownership professional investment institution with state-owned capital participation. Wenzhou Capital focuses on the biopharmaceutical investment sector, strategically positioning itself in science and technology innovation enterprises that align with national healthcare reform trends, possess international competitiveness, and demonstrate sustainable development potential. The team at Wenzhou Capital comprises members with extensive backgrounds in biopharmaceutical research, industry, and investment. Adhering to prudent and rational investment principles, the firm is committed to sincerely supporting enterprise growth. It has successively invested in competitive sci-tech biopharmaceutical companies such as Zhonghui Yuantong, I-Mab Biopharma, Tongyuan Kang, GenFleet Therapeutics, and Puguang Biology.

Songze Capital is a healthcare investment fund based in Shanghai Zhangjiang Hi-Tech Park, specializing in the biopharmaceutical sector. It has invested in numerous outstanding enterprises across areas such as small-molecule drugs, peptide therapeutics, antibody-based medicines, gene therapy, medical devices, and diagnostic technologies. The team boasts extensive investment experience, emphasizing the industry foresight of entrepreneurial projects, the technical expertise of their teams, and the feasibility of market commercialization. Post-investment, the fund prioritizes portfolio management and value-added services, actively connecting companies with industrial and financing resources, collaborating with entrepreneurs to address development challenges, and supporting the growth and expansion of its portfolio companies.

Shandong Shunjie Health Industry Co., Ltd., a subsidiary of Shandong Baiyun Pharmaceutical, is headquartered in Jinan City. The company is dedicated to the pharmaceutical supply chain sector for private hospitals, aiming to provide highly personalized solutions through superior medication usage options, greater value, and premium services. By maintaining close partnerships with numerous pharmaceutical manufacturers, the company holds significant pricing advantages. Its business operations cover China, establishing a professional pharmaceutical service system for its clients. Key clients include Hygeia Healthcare, Hongxin Health, and Shulan Healthcare. Throughout its continuous growth and expansion, the company consistently enhances product quality and service standards, adhering to a customer-centric approach and striving to create greater value for both its clients and society.